Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Moxidectin is indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older, with potential use against Strongyloides stercoralis, Trichuris trichiura, and other soil-transmitted helminthiasis.
• Two studies focused on assessing moxidectin's safety and efficacy not just for onchocerciasis but also for other helminthic infections.
• There was no direct comparison provided between moxidectin and other antiparasitic medications. However, moxidectin may have synergistic or at least non-inferior effects when used with other antiparasitics.
• Studies underscored the importance of moxidectin in possibly complementing existing treatments for soil-transmitted helminths, especially in resource-limited countries where these infections are prevalent.
• In both human and non-human applications, such as treating endo-and ecto-parasites across various mammalian species, moxidectin appears to display a generally favorable safety profile with most adverse effects being mild and self-resolving.
• Further research is needed to assess its efficacy across a broader array of species, indicating existing limitations in the current scope of research.